PMID- 21479586
OWN - NLM
STAT- MEDLINE
DCOM- 20110920
LR  - 20211020
IS  - 1865-3774 (Electronic)
IS  - 0925-5710 (Linking)
VI  - 93
IP  - 5
DP  - 2011 May
TI  - Durable hematological response and improvement of nephrotic syndrome on 
      thalidomide therapy in a patient with refractory light chain deposition disease.
PG  - 673-676
LID - 10.1007/s12185-011-0829-4 [doi]
AB  - Light chain deposition disease (LCDD) is a rare disease for which an optimal 
      treatment is not yet available. Here, we report the clinical course of a 
      32-year-old woman with LCDD who was successfully treated with thalidomide. She 
      presented with nephrotic syndrome. Based on the renal biopsy findings and the 
      presence of monoclonal immunoglobulin light chains in her serum and urine, LCDD 
      was diagnosed. Prednisolone and cytotoxic chemotherapy used for multiple myeloma 
      proved ineffective. We initiated administration of thalidomide (100 mg daily) and 
      dexamethasone (20 mg for 4 days per month). After 8 months of treatment, she 
      achieved complete hematological remission, defined as the disappearance of 
      monoclonal protein and a normalized free light chain ratio, which led to 
      improvement of her renal insufficiency. She has shown sustained hematological and 
      organ response for 31 months with thalidomide therapy. Thus, thalidomide therapy 
      seems to be a promising approach to the treatment of LCDD.
FAU - Fujita, Haruyuki
AU  - Fujita H
AD  - Department of Hematology and Oncology, Graduate School of Medicine, Kyoto 
      University, 54 Shogoin Kawaharacho Sakyo-ku, Kyoto, 606-8507, Japan.
FAU - Hishizawa, Masakatsu
AU  - Hishizawa M
AD  - Department of Hematology and Oncology, Graduate School of Medicine, Kyoto 
      University, 54 Shogoin Kawaharacho Sakyo-ku, Kyoto, 606-8507, Japan. 
      hishiza@kuhp.kyoto-u.ac.jp.
FAU - Sakamoto, Soichiro
AU  - Sakamoto S
AD  - Department of Hematology and Oncology, Graduate School of Medicine, Kyoto 
      University, 54 Shogoin Kawaharacho Sakyo-ku, Kyoto, 606-8507, Japan.
FAU - Kondo, Tadakazu
AU  - Kondo T
AD  - Department of Hematology and Oncology, Graduate School of Medicine, Kyoto 
      University, 54 Shogoin Kawaharacho Sakyo-ku, Kyoto, 606-8507, Japan.
FAU - Kadowaki, Norimistu
AU  - Kadowaki N
AD  - Department of Hematology and Oncology, Graduate School of Medicine, Kyoto 
      University, 54 Shogoin Kawaharacho Sakyo-ku, Kyoto, 606-8507, Japan.
FAU - Ishikawa, Takayuki
AU  - Ishikawa T
AD  - Department of Hematology and Oncology, Graduate School of Medicine, Kyoto 
      University, 54 Shogoin Kawaharacho Sakyo-ku, Kyoto, 606-8507, Japan.
FAU - Itoh, Junji
AU  - Itoh J
AD  - Department of Laboratory Medicine, Nagoya City Midori General Hospital, Nagoya, 
      Japan.
FAU - Fukatsu, Atsushi
AU  - Fukatsu A
AD  - Department of Nephrology, Graduate School of Medicine, Kyoto University, Kyoto, 
      Japan.
FAU - Uchiyama, Takashi
AU  - Uchiyama T
AD  - Department of Hematology and Oncology, Graduate School of Medicine, Kyoto 
      University, 54 Shogoin Kawaharacho Sakyo-ku, Kyoto, 606-8507, Japan.
FAU - Takaori-Kondo, Akifumi
AU  - Takaori-Kondo A
AD  - Department of Hematology and Oncology, Graduate School of Medicine, Kyoto 
      University, 54 Shogoin Kawaharacho Sakyo-ku, Kyoto, 606-8507, Japan.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20110409
PL  - Japan
TA  - Int J Hematol
JT  - International journal of hematology
JID - 9111627
RN  - 0 (Immunoglobulin Light Chains)
RN  - 0 (Immunologic Factors)
RN  - 4Z8R6ORS6L (Thalidomide)
RN  - 7S5I7G3JQL (Dexamethasone)
SB  - IM
MH  - Adult
MH  - Dexamethasone/administration & dosage/therapeutic use
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Immunoglobulin Light Chains/*blood/chemistry
MH  - Immunologic Factors/*administration & dosage/therapeutic use
MH  - Kidney/*metabolism/pathology
MH  - Multiple Myeloma/drug therapy
MH  - Nephrotic Syndrome/*blood/*drug therapy/pathology
MH  - Remission Induction/*methods
MH  - Thalidomide/*administration & dosage/therapeutic use
EDAT- 2011/04/12 06:00
MHDA- 2011/09/21 06:00
CRDT- 2011/04/12 06:00
PHST- 2010/09/15 00:00 [received]
PHST- 2011/03/22 00:00 [accepted]
PHST- 2011/03/07 00:00 [revised]
PHST- 2011/04/12 06:00 [entrez]
PHST- 2011/04/12 06:00 [pubmed]
PHST- 2011/09/21 06:00 [medline]
AID - 10.1007/s12185-011-0829-4 [pii]
AID - 10.1007/s12185-011-0829-4 [doi]
PST - ppublish
SO  - Int J Hematol. 2011 May;93(5):673-676. doi: 10.1007/s12185-011-0829-4. Epub 2011 
      Apr 9.